TITLE

Disease Modifying Therapy in Multiple Sclerosis

AUTHOR(S)
Williams, U. E.; Oparah, S. K.; Philip-Ephraim, E. E.
PUB. DATE
January 2014
SOURCE
ISRN Otolaryngology;2014, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammatory demyelination and axonal degeneration. It is the commonest cause of permanent disability in young adults. Environmental and genetic factors have been suggested in its etiology. Currently available disease modifying drugs are only effective in controlling inflammation but not prevention of neurodegeneration or accumulation of disability. Search for an effective neuroprotective therapy is at the forefront of multiple sclerosis research.
ACCESSION #
100567884

 

Related Articles

  • Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment. De Santi, L.; Polimeni, G.; Cuzzocrea, S.; Esposito, E.; Sessa, E.; Annunziata, P.; Bramanti, P. // Current Medicinal Chemistry;Apr2011, Vol. 18 Issue 12, p1775 

    No abstract available.

  • A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approaches. Bashinskaya, V.; Kulakova, O.; Boyko, A.; Favorov, A.; Favorova, O. // Human Genetics;Nov2015, Vol. 134 Issue 11/12, p1143 

    Multiple sclerosis (MS) is a common complex neurodegenerative disease of the central nervous system. It develops with autoimmune inflammation and demyelination. Genome-wide association studies (GWASs) serve as a powerful tool for investigating the genetic architecture of MS and are generally...

  • IL-17A in Autoimmune Inflammation of the Central Nervous System: A Promising Therapeutic Target in Multiple Sclerosis? Ciric, Bogoljub; Rostami, Abdolmohamad // Open Autoimmunity Journal;2010 Special Issue 3, p171 

    Discovery of the IL-23/Th17 axis brought to an end the era of the Th1/Th2 paradigm and radically advanced our understanding of autoimmunity. Experimental autoimmune encephalitis (EAE), an animal model of multiple sclerosis (MS), was highly instrumental in discovery of the IL-23/Th17 axis and the...

  • Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-κB. Taoufik, Era; Tseveleki, Vivian; Chu, Seung Y.; Tselios, Theodore; Karin, Michael; Lassmann, Hans; Szymkowski, David E.; Probert, Lesley // Brain: A Journal of Neurology;Sep2011, Vol. 134 Issue 9, p2722 

    Tumour necrosis factor mediates chronic inflammatory pathologies including those affecting the central nervous system, but non-selective tumour necrosis factor inhibitors exacerbate multiple sclerosis. In addition, TNF receptor SF1A, which encodes one of the tumour necrosis factor receptors, has...

  • Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms. Levin, Michael C.; Douglas, Joshua N.; Meyers, Lindsay; Sangmin Lee; Yoojin Shin; Gardner, Lidia A. // Degenerative Neurological & Neuromuscular Disease;2014, Vol. 4, p49 

    Multiple sclerosis (MS) is a complex autoimmune disease that impairs the central nervous system (CNS). The neurological disability and clinical course of the disease is highly variable and unpredictable from one patient to another. The cause of MS is still unknown, but it is thought to occur in...

  • The Multifaceted Role of Interferon-γ in Central Nervous System Autoimmune Demyelination. Sanvito, Lara; Constantinescu, Cris S.; Gran, Bruno; 't Hart, Bert A. // Open Autoimmunity Journal;2010 Special Issue 3, p151 

    Extensive research has been devoted to the study of IFN-γ function in several autoimmune diseases. Previously considered the hallmark of Th1 differentiation and pro-inflammatory responses, it has soon become evident that this pivotal cytokine plays a much more complex role than initially...

  • Multiple Sclerosis: Autoimmune Disease or Autoimmune Reaction? Stys, Peter K. // Canadian Journal of Neurological Sciences;Sep2010 Supplement 2, Vol. 37, pS16 

    Multiple sclerosis (MS) is traditionally considered an autoimmune inflammatory demyelinating disease of the central nervous system (CNS) with much knowledge available to support this view. However, this characterization implies that the primary event is an aberrant immune response directed at...

  • The perfect crime? CCSVI not leaving a trace in MS. Christoph A Mayer // Journal of Neurology, Neurosurgery & Psychiatry;Apr2011, Vol. 82 Issue 4, p436 

    BACKGROUND: Multiple sclerosis (MS) is a chronic, inflammatory demyelinating disease of the central nervous system, believed to be triggered by an autoimmune reaction to myelin. Recently, a fundamentally different pathomechanism termed ‘chronic cerebrospinal venous insufficiency’...

  • Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis. Huang, DeRen; Rae-Grant, Alexander // Central Nervous System Agents in Medicinal Chemistry;Mar2009, Vol. 9 Issue 1, p20 

    Multiple sclerosis (MS) is a disorder of the central nervous system (CNS). It is characterized by episodic and progressive neurological dysfunction resulting from inflammatory and autoimmune reactions, myelin loss, conduction block, oligodendrocyte pathology, gliosis, and axonal loss in CNS....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics